Establishment Labs (NASDAQ:ESTA) Director Sells $2,446,125.00 in Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $65.23, for a total value of $2,446,125.00. Following the transaction, the director owned 1,182,504 shares of the company’s stock, valued at $77,134,735.92. This represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total value of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total value of $2,048,730.75.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA opened at $67.08 on Friday. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51. Establishment Labs Holdings Inc. has a 12 month low of $28.67 and a 12 month high of $83.31. The stock has a 50 day moving average of $67.00 and a 200-day moving average of $64.30. The company has a market capitalization of $1.97 billion, a P/E ratio of -38.55 and a beta of 1.08.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The company had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. During the same period in the previous year, the company posted ($1.19) EPS. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, equities research analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on ESTA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Needham & Company LLC lifted their price target on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Stephens lifted their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, BTIG Research lifted their price target on Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus target price of $86.86.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its holdings in Establishment Labs by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after acquiring an additional 299 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in Establishment Labs by 5.8% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company’s stock valued at $261,000 after acquiring an additional 350 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in Establishment Labs by 7.3% in the 4th quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock valued at $641,000 after acquiring an additional 600 shares in the last quarter. Swiss National Bank raised its holdings in Establishment Labs by 1.8% in the 4th quarter. Swiss National Bank now owns 34,200 shares of the company’s stock valued at $2,492,000 after acquiring an additional 600 shares in the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in Establishment Labs in the 4th quarter valued at $47,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.